| Who it’s for | Food, supplement, cosmetic, medical device and drug companies, online sellers, importers, and manufacturers that have received FDA enforcement correspondence |
| What’s covered | Warning Letters, untitled letters, Form 483 observations, FDA and FTC joint letters, corrective action plans, FDA meetings, and close-out requests |
| Response deadline | FDA typically requests a written response within 15 business days |
| Public record | Warning Letters are posted on FDA’s website and responses can be requested under FOIA |
| Goal | Correct the violations, satisfy FDA, and obtain a close-out letter |
What Is an FDA Warning Letter?
A Warning Letter is FDA’s formal notice that it believes a company has committed significant violations of the FD&C Act or related regulations. It usually follows an inspection, a product sample, a review of labeling or websites, or an import finding. It is typically FDA’s first formal enforcement step, and it gives the company an opportunity to correct the problems voluntarily.
Every Warning Letter identifies the violations, explains the legal basis, and asks the company to respond in writing, usually within 15 business days. The response should explain what the company has done and will do to correct each violation and prevent it from happening again.
Warning Letters are advisory, but they should never be treated as informal. FDA uses the response to decide whether the matter is resolved or whether stronger action is needed.
Why Your Warning Letter Response Matters
An inadequate response, or no response at all, often leads to more formal measures. These can include:
- Product seizures of violative inventory
- Injunctions and consent decrees that place operations under court and FDA oversight
- Import Alerts that allow FDA to detain your shipments without examination
- Civil money penalties in product areas where FDA has that authority, such as medical devices
- Criminal referral in serious or repeated cases
- Commercial fallout, including retailer delistings, marketplace suspensions, investor concerns, and consumer lawsuits citing the public letter
A well-prepared response is often the difference between a closed matter and years of escalating enforcement.
Just received a Warning Letter or Form 483? Your 15-day window has already started. Contact an FDA attorney today to begin your response.
Schedule a ConsultationCommon Warning Letter Violations, by Product Type
| Product Type | Key Regulations | Common Violations Cited |
|---|---|---|
| Food and beverages | 21 CFR Parts 101, 117, 120, 123; FSVP | Preventive controls failures, sanitation, juice or seafood HACCP, allergen labeling, missing FSVP |
| Dietary supplements | DSHEA; 21 CFR Parts 101 and 111 | Disease claims, unapproved new drug charges, cGMP failures, missing identity testing, labeling errors |
| Cosmetics | FD&C Act; MoCRA | Drug claims such as treating acne or regrowing hair, unapproved color additives, adulteration |
| Medical devices | 21 CFR Parts 803, 807, 820 | Quality system failures, missing complaint or MDR procedures, marketing without clearance or approval |
| Drugs and OTC products | 21 CFR Parts 210 and 211; OTC monographs | cGMP violations, unapproved new drugs, non-monograph claims, data integrity |
| Online sellers | FD&C Act; FTC Act | Unsupported health claims on websites, social media, and marketplace listings |
What’s Included in Our Warning Letter Response Services
- Legal and regulatory analysis of each violation FDA cites and the basis for it
- Root cause assessment so corrections address the real problem, not just the symptom
- Corrective and preventive action plans with realistic timelines
- Response drafting that answers every item in the letter within the required timeframe
- Supporting documentation, including revised labels, procedures, training records and test results
- Confidentiality requests for trade secrets and commercial information in your response
- FDA communication, including extension requests, follow-up updates, and regulatory meetings
- Close-out support through verification and reinspection
- Ongoing compliance guidance to prevent repeat violations
Core Service Areas
Warning Letter Analysis
We start by reviewing the letter against the underlying law, inspection records, product labels and marketing. Some charges are clear violations that need prompt correction. Others rest on a misreading of the facts or the regulations and can be addressed with evidence. Knowing which is which shapes the entire response.
Corrective Action Planning
FDA expects more than a promise to do better. It wants to see that the company found the root cause, fixed the specific problem, checked whether the issue affects other products or processes, and put systems in place to prevent a recurrence. We work with your team to build a corrective action plan FDA can verify.
Drafting the Response
A strong response is organized, specific and supported. It addresses each violation in the order FDA raised it, explains what has been corrected, gives timelines for any work still in progress, and attaches the evidence. When corrections will take longer than 15 business days, the response should say so and explain why. Because responses can be released under FOIA, we mark confidential information appropriately.
Form 483 Responses
A Form 483 lists the observations FDA investigators make at the end of an inspection. It is not a final agency finding, but it often comes before a Warning Letter. FDA generally considers Form 483 responses received within 15 business days before deciding whether to issue a Warning Letter. A thorough, timely 483 response is one of the best ways to avoid a Warning Letter altogether.
Claims and Marketing Warning Letters
Many Warning Letters to supplement, cosmetic and food companies focus on claims made online, including websites, social media posts, and customer testimonials that the company shares. Some are issued jointly with the FTC. We identify every problem claim, revise or remove it across all channels, and document the changes for FDA. Learn more about label and marketing reviews.
Close-Out and Follow-Up
After the response, FDA may request updates, hold a regulatory meeting, or schedule a follow-up inspection. Once FDA confirms the corrections, it may issue a close-out letter. We manage those communications and prepare your team for any reinspection.
Our Warning Letter Response Process
- Immediate intake: send us the Warning Letter or Form 483, inspection documents, and relevant labels or records
- Analysis: we assess each violation, its legal basis, and your exposure
- Corrective plan: we work with your team to define root causes, fixes and timelines
- Response: we draft and submit a complete, supported response before the deadline
- Follow-through: we handle FDA updates, meetings and reinspection through close-out
The 15-business-day window leaves little time for corrective work. Contact us as soon as you receive FDA correspondence.
Why Work With an FDA Attorney on Your Response
A Warning Letter response is a legal document submitted to a federal agency. It can shape future enforcement, litigation, and your company’s public record.
- Attorney-client privilege. Internal investigations into what went wrong are generally protected when directed by counsel.
- Careful admissions. We commit to corrections without making statements that create unnecessary legal exposure.
- Litigation awareness. Public Warning Letters are often cited in consumer class actions. We draft with that risk in mind.
- Escalation readiness. If FDA moves toward seizure, injunction or an Import Alert, your attorney already knows the file.
Frequently Asked Questions
- What is an FDA Warning Letter?
- An FDA Warning Letter is a formal notice that FDA believes a company has committed significant violations of the laws it enforces. It is usually the agency’s first formal enforcement step and gives the company a chance to correct the violations voluntarily before FDA takes further action.
- How long do I have to respond to an FDA Warning Letter?
- FDA typically asks for a written response within 15 business days of receipt. If corrections will take longer, the response should explain the reason and give a timeline for completing them.
- What happens if I ignore an FDA Warning Letter?
- Failing to respond, or responding inadequately, can lead to further enforcement such as product seizure, injunction, Import Alerts, civil money penalties in some product areas, or referral for criminal prosecution.
- Are FDA Warning Letters made public?
- Yes. FDA posts Warning Letters on its website, usually with limited redactions. Company responses can also be requested under the Freedom of Information Act, so confidential business information should be clearly marked.
- What is the difference between a Form 483 and a Warning Letter?
- A Form 483 lists observations made by FDA investigators at the end of an inspection. A Warning Letter is issued later by FDA and states the agency’s position that violations occurred. A strong Form 483 response filed within 15 business days can sometimes prevent a Warning Letter.
- What is an FDA close-out letter?
- A close-out letter confirms that FDA has completed its evaluation and that the company’s corrective actions appear to address the violations. FDA usually issues it only after verifying the corrections, which may include a follow-up inspection.
- What is an untitled letter?
- An untitled letter addresses violations FDA considers less serious than those in a Warning Letter. It still requires attention and a response, since unresolved issues can lead to a Warning Letter.
- Can a Warning Letter affect my business beyond FDA?
- Yes. Warning Letters can affect retailer and marketplace relationships, investor due diligence, export certificates, and consumer litigation, since plaintiffs often cite public Warning Letters in lawsuits.
Received FDA correspondence? Contact us today so your response is filed on time and done right.
Toll-free: (866) 785-0873
Direct: (305) 507-9843
Email: contact@giannamore-law.com
Schedule a ConsultationThis page provides general information and is not legal advice. Reading it does not create an attorney-client relationship. FDA procedures and timelines may change; contact our office for advice about your specific matter.